文献速递产科母胎医学

何时给予阿司匹林预防子痫前期:贝叶斯决策理论的应用

When to give aspirin to prevent preeclampsia: application of Bayesian decision theory.
PubMed 文献 · Am J Obstet Gynecol · 2022-01-01

本研究从贝叶斯决策理论视角比较普遍治疗、分层治疗与不治疗三种阿司匹林预防策略。基于早孕期筛查研究和阿司匹林随机试验证据,在每预防1例早产子痫前期需治疗10至1000名女性的交换率范围内,风险分层靶向治疗的净获益高于不治疗或普遍治疗。结论认为应避免普遍使用阿司匹林,应采用基于风险的筛查,并综合考虑获益与危害及检出率、假阳性率、筛查阳性率来确定用药 cutoff。

要点

  • 在每预防1例早产子痫前期需治疗10至1000名女性的交换率范围内,风险分层靶向治疗的净获益高于不治疗或普遍治疗。
  • 普遍使用阿司匹林应避免。
  • 应采用基于风险的筛查,阿司匹林用药 cutoff 应综合考虑获益与危害及检出率、假阳性率、筛查阳性率来确定。

核心结论

  • 普遍使用阿司匹林应避免;应采用基于风险的筛查,用药 cutoff 应综合考虑获益与危害及检出率、假阳性率、筛查阳性率来确定。

研究设计与样本

  • 从贝叶斯决策理论视角评估普遍治疗、分层治疗和不治疗三种阿司匹林预防策略。
  • 早产子痫前期风险证据来自 Screening programme for pre-eclampsia 研究(早孕期筛查研究)。
  • 阿司匹林效果证据来自 Aspirin for Evidence-Based Preeclampsia Prevention 试验(阿司匹林 vs 安慰剂预防早产子痫前期的试验)。
  • 通过回答「每预防1例早产子痫前期最多应治疗多少名女性」来设定获益与危害的交换率,并在广泛交换率范围内比较各策略。

主要发现

  • 对于每预防1例早产子痫前期需治疗10至1000名女性的交换率,对早产子痫前期高风险女性进行风险评估和靶向治疗获得的净获益高于不治疗或普遍使用阿司匹林。

临床怎么用

  • 作者认为应避免普遍使用阿司匹林,应采用基于风险的筛查,并根据获益与危害的权衡及检出率、假阳性率、筛查阳性率来确定用药 cutoff。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is good evidence that first-trimester assessment of the risk for preterm preeclampsia and treatment of the high-risk group with aspirin reduces the incidence of preterm preeclampsia. Furthermore, there is evidence that aspirin is associated with an increased risk of maternal and neonatal hemorrhagic complications. Against this background, there are ongoing debates whether aspirin should be recommended for all women or to a subpopulation of women predicted to be at increased risk of developing preeclampsia. Moreover, if a strategy of the prediction and prevention of preterm preeclampsia is to be used, what method should be used for the prediction, and what risk cutoff should be used to decide on who to treat? OBJECTIVE: This study aimed to compare the policies of universal treatment, stratified treatment, and no treatment with aspirin. STUDY DESIGN: Decisions about aspirin prophylaxis were considered from the perspective of the Bayesian decision theory. Using this approach, the treatment policies were evaluated for risks of preterm preeclampsia, effects of aspirin, and trade-offs between the harms and benefits of the treatment. Evidence on the risk of preterm preeclampsia was taken from the Screening programme for pre-eclampsia study, which was a first-trimester screening study for the prediction of preeclampsia. Evidence of the effect of aspirin was taken from the Aspirin for Evidence-Based Preeclampsia Prevention trial, which was a trial of aspirin vs placebo in the prevention of preterm preeclampsia. The trade-off between the benefits and harms of aspirin was specified by addressing the question, "What is the maximum number of women that should be treated to prevent 1 case of preterm preeclampsia?" The number can be considered as an exchange rate between the harms and benefits of using aspirin to prevent preterm PE. Given the uncertainty about the harms associated with aspirin, the treatment policies were compared across a wide range of exchange rates. RESULTS: For exchange rates between 10 and 1000 women treated with aspirin to prevent 1 case of preterm preeclampsia, the net benefit achieved from the risk assessment and targeted treatment of women at high risk of preterm preeclampsia was higher than that from women with no treatment or women with universal treatment with aspirin. CONCLUSION: Universal treatment with aspirin should be avoided. Risk-based screening should be used, and the cutoff for taking aspirin should be determined from the consideration of the trade-off between the benefits and harms and detection, false-positive, and screen-positive rates.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wright D, Wright A, Tan MY, et al. When to give aspirin to prevent preeclampsia: application of Bayesian decision theory. Am J Obstet Gynecol. 2022. PMID: 35177216. doi:10.1016/j.ajog.2021.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。